These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28150517)

  • 1. Human biology-based drug safety evaluation: scientific rationale, current status and future challenges.
    Kenna JG
    Expert Opin Drug Metab Toxicol; 2017 May; 13(5):567-574. PubMed ID: 28150517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury.
    Weaver RJ; Betts C; Blomme EAG; Gerets HHJ; Gjervig Jensen K; Hewitt PG; Juhila S; Labbe G; Liguori MJ; Mesens N; Ogese MO; Persson M; Snoeys J; Stevens JL; Walker T; Park BK
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):767-782. PubMed ID: 28604124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiosyncratic drug-induced liver injury: an update on the 2007 overview.
    Hussaini SH; Farrington EA
    Expert Opin Drug Saf; 2014 Jan; 13(1):67-81. PubMed ID: 24073714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced liver injury: a safety review.
    García-Cortés M; Ortega-Alonso A; Lucena MI; Andrade RJ;
    Expert Opin Drug Saf; 2018 Aug; 17(8):795-804. PubMed ID: 30059261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high content screening assay to predict human drug-induced liver injury during drug discovery.
    Persson M; Løye AF; Mow T; Hornberg JJ
    J Pharmacol Toxicol Methods; 2013; 68(3):302-13. PubMed ID: 23933113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity.
    Li AP
    Chem Biol Interact; 2002 Nov; 142(1-2):7-23. PubMed ID: 12399152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling cellular pathways contributing to drug-induced liver injury by dynamical modeling.
    Kuijper IA; Yang H; Van De Water B; Beltman JB
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):5-17. PubMed ID: 27609146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced liver injury: an overview over the most critical compounds.
    Björnsson ES
    Arch Toxicol; 2015 Mar; 89(3):327-34. PubMed ID: 25618544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of severe adverse drug reactions using pharmacogenetic biomarkers.
    Tohkin M; Ishiguro A; Kaniwa N; Saito Y; Kurose K; Hasegawa R
    Drug Metab Pharmacokinet; 2010; 25(2):122-33. PubMed ID: 20460818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury.
    Amacher DE
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):335-47. PubMed ID: 22288564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced liver injury.
    Kaplowitz N
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S44-8. PubMed ID: 14986274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-content analysis in toxicology: screening substances for human toxicity potential, elucidating subcellular mechanisms and in vivo use as translational safety biomarkers.
    O'Brien PJ
    Basic Clin Pharmacol Toxicol; 2014 Jul; 115(1):4-17. PubMed ID: 24641563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
    Thompson RA; Isin EM; Ogese MO; Mettetal JT; Williams DP
    Chem Res Toxicol; 2016 Apr; 29(4):505-33. PubMed ID: 26735163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced liver injury: what was new in 2013?
    Chalhoub WM; Sliman KD; Arumuganathan M; Lewis JH
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):959-80. PubMed ID: 24746272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse Drug Reactions: Type A (Intrinsic) or Type B (Idiosyncratic).
    Iasella CJ; Johnson HJ; Dunn MA
    Clin Liver Dis; 2017 Feb; 21(1):73-87. PubMed ID: 27842776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury.
    Benesic A; Rotter I; Dragoi D; Weber S; Leitl A; Buchholtz ML; Gerbes AL
    Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1488-1494.e5. PubMed ID: 29723689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting idiosyncratic drug-induced liver injury: some recent advances.
    Chen M; Borlak J; Tong W
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):721-3. PubMed ID: 24857265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.